AU2023223413A1 - Bispecific binding proteins against alarmins and uses thereof - Google Patents

Bispecific binding proteins against alarmins and uses thereof Download PDF

Info

Publication number
AU2023223413A1
AU2023223413A1 AU2023223413A AU2023223413A AU2023223413A1 AU 2023223413 A1 AU2023223413 A1 AU 2023223413A1 AU 2023223413 A AU2023223413 A AU 2023223413A AU 2023223413 A AU2023223413 A AU 2023223413A AU 2023223413 A1 AU2023223413 A1 AU 2023223413A1
Authority
AU
Australia
Prior art keywords
antibody
bispecific binding
seq
amino acid
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023223413A
Other languages
English (en)
Inventor
Chin Wai HUI
Lik Hang LAM
Shui On LEUNG
Weimin Li
Nan SONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinomab Bioscience Ltd
Original Assignee
Sinomab Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinomab Bioscience Ltd filed Critical Sinomab Bioscience Ltd
Publication of AU2023223413A1 publication Critical patent/AU2023223413A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2023223413A 2022-02-24 2023-02-23 Bispecific binding proteins against alarmins and uses thereof Pending AU2023223413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313483P 2022-02-24 2022-02-24
US63/313,483 2022-02-24
PCT/CN2023/077870 WO2023160610A1 (en) 2022-02-24 2023-02-23 Bispecific binding proteins against alarmins and uses thereof

Publications (1)

Publication Number Publication Date
AU2023223413A1 true AU2023223413A1 (en) 2024-10-10

Family

ID=87764833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023223413A Pending AU2023223413A1 (en) 2022-02-24 2023-02-23 Bispecific binding proteins against alarmins and uses thereof

Country Status (11)

Country Link
US (1) US20240409647A1 (https=)
EP (1) EP4482525A1 (https=)
JP (1) JP2025508835A (https=)
KR (1) KR20240161653A (https=)
CN (1) CN119183384A (https=)
AU (1) AU2023223413A1 (https=)
CA (1) CA3253236A1 (https=)
CL (1) CL2024002512A1 (https=)
IL (1) IL315208A (https=)
MX (1) MX2024010459A (https=)
WO (1) WO2023160610A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118126A1 (zh) * 2023-12-05 2025-06-12 中国抗体制药有限公司 抗il-17rb抗体、或其抗原结合片段或组合物的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
AU582288B2 (en) 1986-03-07 1989-03-16 Damon Biotech Inc. Vector and method for achieving high level expression in eukaryotic cells
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
US9840557B2 (en) * 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
MX2018013038A (es) * 2016-04-27 2019-03-28 Pfizer Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
GB201820006D0 (en) 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
PE20230252A1 (es) * 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
GB202018015D0 (en) * 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer

Also Published As

Publication number Publication date
WO2023160610A1 (en) 2023-08-31
KR20240161653A (ko) 2024-11-12
MX2024010459A (es) 2024-11-08
CL2024002512A1 (es) 2024-11-22
CA3253236A1 (en) 2023-08-31
IL315208A (en) 2024-10-01
JP2025508835A (ja) 2025-04-10
US20240409647A1 (en) 2024-12-12
EP4482525A1 (en) 2025-01-01
CN119183384A (zh) 2024-12-24

Similar Documents

Publication Publication Date Title
US20250154241A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20220267476A1 (en) Multispecific antibody constructs
AU2016370659B2 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
CN105481983B (zh) 4-1bb结合分子
CA2959551C (en) Anti-tnf-/anti-il-23 bispecific antibodies
JP6931750B2 (ja) 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2022084782A (ja) 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
EP2970467B1 (en) Anti-cd52 antibodies
KR20250153216A (ko) Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
US20240409647A1 (en) Bispecific binding proteins against alarmins and uses thereof
US10940212B2 (en) IL-21 agonist antibodies and methods of treatment using same
TW202216198A (zh) 使用抗組織因子抗體之炎性疾病治療
HK40120136A (zh) 针对警报素的双特异性结合蛋白及其用途
KR20180089521A (ko) Tnf 알파에 결합하는 항체 분자
JP7603061B2 (ja) Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用
US20230064703A1 (en) Anti-gitr antibodies and uses thereof
KR20250162899A (ko) 항-il-25 항체 및 이의 사용 방법
BR122025021892A2 (pt) Células hospedeiras
HK1187627B (en) 4-1bb binding molecules